Amy Wise,Jingyao Li,Mai Yamakawa,Joseph Loureiro,Brant Peterson,Kathleen Worringer,Rajeev Sivasankaran,Jose-Alberto Palma,Laura Mitic,Hilary W Heuer,Argentina Lario-Lago,Adam M Staffaroni,Annie Clark,Jack Taylor,Peter A Ljubenkov,Lawren Vandevrede,Lea T Grinberg,Salvatore Spina,William W Seeley,Bruce L Miller,Bradley F Boeve,Bradford C Dickerson,Murray Grossman,Irene Litvan,Alexander Pantelyat,Maria Carmela Tartaglia,Zihan Zhang,Anne-Marie A Wills,Jessica Rexach,Julio C Rojas,Adam L Boxer,as the 4-Repeat Tauopathy Neuroimaging Initiative

Abstract:Background and objectives: Identification of fluid biomarkers for progressive supranuclear palsy (PSP) is critical to enhance therapeutic development. We implemented unbiased DNA aptamer (SOMAmer) proteomics to identify novel CSF PSP biomarkers. Methods: This is a cross-sectional study in original (18 clinically diagnosed PSP-Richardson syndrome [PSP-RS], 28 cognitively healthy controls]), validation (23 PSP-RS, 26 healthy controls), and neuropathology-confirmed (21 PSP, 52 non-PSP frontotemporal lobar degeneration) cohorts. Participants were recruited through the University of California, San Francisco, and the 4-Repeat Neuroimaging Initiative. The original and neuropathology cohorts were analyzed with the SomaScan platform version 3.0 (5026-plex) and the validation cohort with version 4.1 (7595-plex). Clinical severity was measured with the PSP Rating Scale (PSPRS). CSF proteomic data were analyzed to identify differentially expressed targets, implicated biological pathways using enrichment and weighted consensus gene coexpression analyses, diagnostic value of top targets with receiver-operating characteristic curves, and associations with disease severity with linear regressions. Results: A total of 136 participants were included (median age 70.6 ± 8 years, 68 [50%] women). One hundred fifty-five of 5,026 (3.1%), 959 of 7,595 (12.6%), and 321 of 5,026 (6.3%) SOMAmers were differentially expressed in PSP compared with controls in original, validation, and neuropathology-confirmed cohorts, with most of the SOMAmers showing reduced signal (83.1%, 95.1%, and 73.2%, respectively). Three coexpression modules were associated with PSP across cohorts: (1) synaptic function/JAK-STAT (β = -0.044, corrected p = 0.002), (2) vesicle cytoskeletal trafficking (β = 0.039, p = 0.007), and (3) cytokine-cytokine receptor interaction (β = -0.032, p = 0.035) pathways. Axon guidance was the top dysregulated pathway in PSP in original (strength = 1.71, p < 0.001), validation (strength = 0.84, p < 0.001), and neuropathology-confirmed (strength = 0.78, p < 0.001) cohorts. A panel of axon guidance pathway proteins discriminated between PSP and controls in original (area under the curve [AUC] = 0.924), validation (AUC = 0.815), and neuropathology-confirmed (AUC = 0.932) cohorts. Two inflammatory proteins, galectin-10 and cytotoxic T lymphocyte-associated protein-4, correlated with PSPRS scores across cohorts. Discussion: Axon guidance pathway proteins and several other molecular pathways are downregulated in PSP, compared with controls. Proteins in these pathways may be useful targets for biomarker or therapeutic development.

In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy

Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy

CSF Proteomics in Patients With Progressive Supranuclear Palsy

Alzheimer's-Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy

Association of Insulin-like Growth Factor-1 and Neurofilament Light Chain in Patients with Progressive Supranuclear Palsy

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy

Retinal Thinning as a Marker of Disease Severity in Progressive Supranuclear Palsy

Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

Cerebral tau deposition in co-morbid progressive supranuclear palsy and amyotrophic lateral sclerosis: an [18F]-flortaucipir and 7T MRI study

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription

Progressive Supranuclear Palsy: Subcortical Tau Depositions Are Associated with Cortical Perfusion in Frontal and Limbic Regions

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy

Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy

The associations between common neuroimaging parameters of Progressive Supranuclear Palsy in magnetic resonance imaging and non-specific inflammatory factors - pilot study

Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain

Dominance of Tau Burden in Cortical Over Subcortical Regions Mediates Glymphatic Activity and Clinical Severity in PSP

Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy